All Topics

Subscribe
Article
The EU Pharma Package: The Transferable Exclusivity Voucher Compromise Proposal
Addressing antimicrobial resistance (AMR) is one of the key objectives of the EU’s legislative reform. However, the development pipeline for new effective antimicrobials is obstructed, primarily due to a profound market failure: the low commercial value of the antimicrobial medicinal product market (costly development versus naturally limited market). In short, the market alone cannot deliver the solutions urgently needed to address AMR.
European Union Healthcare
CM
Crowell & Moring LLP
See more
See more